A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer

Investigational New Drugs

Volumn 32, Issue 4, 2014, Pages 746-752

  Azad, Arun A ^a   Beardsley, Emma K ^a   Hotte, Sebastian J ^b   Ellard, Susan L ^a   Klotz, Lawrence ^c   Chin, Joseph ^d   Kollmannsberger, Christian ^a   Mukherjee, Som D ^b   Chi, Kim N ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Bicalutamide; Castration resistant prostate cancer; EGFR; Vandetanib; VEGFR 2

Indexed keywords

ANILIDE; ANTINEOPLASTIC AGENT; BICALUTAMIDE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; NITRILE; PIPERIDINE DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TOLUENESULFONIC ACID DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VEGFA PROTEIN, HUMAN;

AGED; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MALE; METABOLISM; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIAL;

AGED; ANILIDES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; NITRILES; PIPERIDINES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TOSYL COMPOUNDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84904578792     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0091-8     Document Type: Article

References (28)

1. Kucuk O, Fisher E, Moinpour CM, Coleman D, Hussain MH, Sartor AO, Chatta GS, Lowe BA, Eisenberger MA, Crawford ED (2001) Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 58(1):53-58 (Pubitemid 32633935)
2. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ (1998) High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 159(1):149-153 (Pubitemid 27525592)
3. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M (1997) Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 15(8):2928-2938 (Pubitemid 27330021)
4. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM (2001) Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 61(6):2736-2743 (Pubitemid 32685863)
5. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54(20):5474-5478
6. Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP (2002) Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity andmetastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8(8):2714-2724 (Pubitemid 34856361)
7. Festuccia C, Gravina GL, Angelucci A, Millimaggi D, Muzi P, Vicentini C, Bologna M (2005) Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int J Cancer 115(4):630-640. doi:10.1002/ijc.20917 (Pubitemid 40656723)
8. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62(16):4645-4655
9. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62(24):7284-7290 (Pubitemid 36025251)
10. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30(2):134-141. doi:10.1200/JCO.2011.35.5040
11. Chau NG, Haddad RI (2013) Vandetanib for the treatment of medullary thyroid cancer. Clin Cancer Res 19(3):524-529. doi:10.1158/1078-0432.CCR-12-2353
12. Hammarsten P, Halin S, Wikstom P, Henriksson R, Rudolfsson SH, Bergh A (2006) Inhibitory effects of castration in an orthotopicmodel of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition. Clin Cancer Res 12(24):7431-7436. doi:10.1158/1078- 0432.CCR-06-1895 (Pubitemid 46095418)
13. Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, Chen YM, Emerson L, Langmuir P, Manegold C (2012) Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 30(10):1114-1121. doi:10.1200/JCO.2011.36.1709
14. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J, Barlesi F, Langmuir P, Gogov S, Rowbottom JA, Goss GD (2011) Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 29(8):1059-1066. doi:10.1200/JCO.2010.28.5981
15. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT (1997) Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 3(12 Pt 1):2507-2511 (Pubitemid 28133175)
16. Stewart RJ, Panigrahy D, Flynn E, Folkman J (2001) Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 165(2):688-693. doi:10.1097/00005392-200102000-00095 (Pubitemid 32060501)
17. Eisermann K, Broderick CJ, Bazarov A, Moazam MM, Fraizer GC (2013) Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site. Mol Cancer 12:7. doi:10.1186/1476-4598-12- 7
18. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24(1):16-24. doi:10.1200/JCO.2005.02.2574 (Pubitemid 46630489)
19. Chi KN, Ellard SL, Hotte SJ, Czaykowski P, Moore M, Ruether JD, Schell AJ, Taylor S, Hansen C, Gauthier I, Walsh W, Seymour L (2008) A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 19(4):746-751. doi:10.1093/annonc/mdm554 (Pubitemid 351461047)
20. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schoffski P, Scheffold C, Weitzman AL, Hussain M (2013) Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 31(4):412-419. doi:10.1200/JCO.2012.45.0494
21. Ponguta LA, Gregory CW, French FS, Wilson EM (2008) Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J Biol Chem 283(30):20989-21001. doi:10.1074/jbc.M802392200
22. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ (2012) Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30(13):1534-1540. doi:10.1200/JCO.2011.39.4767
23. Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Flechon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Aren O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M (2013) Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 14(8):760-768. doi:10.1016/S1470-2045(13)70184-0
24. Ou Y, Michaelson MD, Sengelov L, Saad F, Houede N, Ostler PJ, Stenzl A, Daugaard G, Jones RJ, Laestadius F, Bahl A, Castellano DE, Gschwend J, Maurina T, Ye D, Chen I, Wang S, Maneval EC, Oudard S (2011) Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). ASCO Meet Abstr 29(15-suppl):4515
25. Pezaro C, Rosenthal MA, Gurney H, Davis ID, Underhill C, Boyer MJ, Kotasek D, Solomon B, Toner GC (2009) An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. Am J Clin Oncol 32(4):338-341. doi:10.1097/COC.0b013e31818b946b
26. Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP, George DJ (2013) A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol Oncol 31(1):82-86. doi:10.1016/j.urolonc.2010.09.018
27. Fleming MT, Sonpavde G, Kolodziej M, Awasthi S, Hutson TE, Martincic D, Rastogi A, Rousey SR, Weinstein RE, Galsky MD, Berry WR, Wang Y, Boehm KA, Asmar L, Rauch MA, Beer TM (2012) Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 10(1):6-14. doi:10.1016/j.clgc.2011.11.003
28. Horti J, Widmark A, Stenzl A, Federico MH, Abratt RP, Sanders N, Pover GM, Bodrogi I (2009) A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm 24(2):175-180. doi:10.1089/cbr.2008.0588